Delek US Holdings, Inc. (DK) Earns "Buy" Rating from Cowen and Company

Cornelia Mascio
Novembre 15, 2017

Also Globenewswire.com published the news titled: "Delek US Holdings to Host Third Quarter 2017 Conference Call on November 9" on October 16, 2017. The stock rose 1.80% or $0.49 reaching $27.72.

About 454,887 shares traded or 68.14% up from the average. (NYSE:DK). Cubist Systematic Strategies Ltd Liability Company has invested 0.09% in Delek US Holdings, Inc. (NYSE:DK) has risen 89.96% since November 14, 2016 and is uptrending. It has outperformed by 73.26% the S&P500. The stock of Delek US Holdings, Inc. (NYSE:DK) rating on Wednesday, July 13. It has outperformed by 108.00% the S&P500.The move comes after 9 months negative chart setup for the $1.70B company. We have $43.68 PT which if reached, will make NASDAQ:FMI worth $119.00M less.

Foundation Medicine, Inc.is a molecular information company. The company has market cap of $1.70 billion. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers.

Analysts await Foundation Medicine Inc (NASDAQ:FMI) to report earnings on February, 28. The 1 year EPS growth rate is 6.80%.

More recent Delek US Holdings, Inc. The Virginia-based Quantitative Investment Ltd Limited Liability Company has invested 0.03% in Foundation Medicine Inc (NASDAQ:FMI). Tower Rech Capital (Trc) has invested 0.01% in Foundation Medicine Inc (NASDAQ:FMI). Goldman Sachs Gp accumulated 40,265 shares or 0% of the stock. 3,442 were accumulated by Legal And General Gp Plc. On the opposite side of that transaction from Dimensional Fund Advisors Lp stood Vanguard Group Inc which added 1.87 million shares to its existing stake, bringing total stake held in DK to 8.49 million shares. 10,590 are owned by Aqr Capital Mngmt Lc. 13,100 were reported by Nine Chapters Cap Management Ltd Liability Corporation. Thompson Siegel Walmsley Llc owns 515,609 shares for 0.16% of their portfolio. The consensus target price is $23.50 with 4 firms rating the stock a strong buy, 7 firms rating the stock a buy, 5 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell. Therefore 42% are positive. Foundation Medicine had 12 analyst reports since July 30, 2015 according to SRatingsIntel. (NYSE:DK) continues to be a formidable company.

A number of research firms have recently weighed in on DK. (NYSE:DK) earned "Outperform" rating by Macquarie Research on Tuesday, October 24. The rating was maintained by UBS on Friday, February 3 with "Buy". The firm earned "Market Perform" rating on Thursday, July 30 by JMP Securities.

Since May 22, 2017, it had 0 insider buys, and 10 sales for $6.18 million activity. Another trade for 20,000 shares valued at $520,000 was sold by Ginzburg Assi. 825 shares were sold by Page Mark T., worth $20,959. Wolfe Research downgraded Delek US Holdings, Inc. (NYSE:DK) from a hold rating to a buy rating in a report issued on Friday. During such technical setups, fundamental investors usually stay away and are careful buying the stock. Also, Director Charles H. Leonard sold 2,500 shares of the company's stock in a transaction dated Tuesday, August 15th. Holmes Donald Norman sold $17,586 worth of stock or 688 shares.

Raymond James has upgraded Delek US Holdings (NYSE:DK) from Outperform to Strong Buy in a report released on 11/13/2017. As per Friday, March 24, the company rating was downgraded by Credit Suisse. Principal Financial Group Inc. grew its holdings in shares of Delek US Holdings by 14.8% during the 1st quarter. (NYSE:DK). Oppenheimer Asset Management Incorporated stated it has 0% of its portfolio in Delek US Holdings, Inc. (NYSE:DK) plunged -1.05% with the closing price of $27.44. The company was maintained on Wednesday, October 18 by RBC Capital Markets. On Friday, September 11 the stock rating was initiated by JP Morgan with "Overweight". The firm has "Sell" rating given on Wednesday, August 5 by Zacks. The rating was upgraded by Bank of America to "Buy" on Tuesday, January 5. Delek US Holdings, Inc. (NYSE:DK) on Monday, November 14 to "Peer Perform" rating. Barclays Capital maintained the shares of DK in report on Tuesday, January 12 with "Overweight" rating. The company was maintained on Thursday, August 3 by RBC Capital Markets.

Investors sentiment decreased to 1.01 in 2017 Q2. Its down 0.26, from 1.27 in 2017Q1. It dropped, as 40 investors sold Delek US Holdings, Inc. shares while 34 reduced holdings.

Analysts await Delek US Holdings, Inc. (NYSE:DK). 15,068 were reported by Bnp Paribas Arbitrage Sa.

Brokerage firms now have a positive stance on shares of TherapeuticsMD, Inc. First Midwest Retail Bank Division invested 0.04% of its portfolio in Delek US Holdings, Inc. (NYSE:DK) for 29,329 shares. Delek US Holdings now has a consensus rating of "Buy" and a consensus target price of $30.00. (NYSE:DK) for 97,294 shares. Citadel Advisors Limited Com reported 632,001 shares. Royal Retail Bank Of Canada has invested 0% in Delek US Holdings, Inc. (NYSE:DK). Indexiq Advsr Ltd Llc reported 1,526 shares. Northern Trust Corp holds 0.01% or 864,046 shares in its portfolio. About shares traded. Delek US Holdings, Inc. (NYSE:DK) or 2.42M shares. This represents a change from most recent open price of 2.61%. Int Grp invested in 0% or 38,251 shares.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE